Medical Device Manufacturing - Cardiac Diagnostics
Strategic Profile
The company achieved FDA clearance for arrhythmia assessment in December 2024 and 12-lead ECG synthesis software in December 2025. HeartBeam ranked #2 worldwide in 12-lead ECG innovation among 243 companies analyzed, second only to GE HealthCare. The company holds over 20 issued patents related to technology enablement.
Cyborg Score Rationale
HeartBeam has achieved significant regulatory milestones (FDA clearances for arrhythmia and 12-lead ECG) and owns differentiated 3D ECG technology with strong patent protection. However, the company faces substantial execution risk as a pre-revenue stage company (with annual revenue of only $750K) with limited cash reserves and challenges with market acceptance.
Top Insights
Cable-free 3D ECG device that synthesizes clinical-grade 12-lead ECG output for portable use
Recent FDA clearances for arrhythmia assessment (Dec 2024) and 12-lead synthesis (Dec 2025) de-risk regulatory pathway
Ranked #2 globally in 12-lead ECG innovation by PatentVest, demonstrating strong IP position
Company transitioning into growth phase with limited launch planned for 2026, plus programs for heart attack detection and extended-wear patch
Named Competitors
Traditional 12-lead ECG Systems — Established market leaders in clinical ECG solutions
Wearable Cardiac Monitoring — Consumer-grade wearable ECG and rhythm monitoring
Remote Cardiac Monitoring — Ambulatory and remote monitoring platforms
Recent Developments
(December 2025) FDA clearance for 12-lead ECG synthesis software
(December 2024) FDA clearance for arrhythmia assessment
(January 2026) Recognized as Global IP and Technology Leader in Portable Cardiac Diagnostics by PatentVest
Open the full interactive HeartBeam, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.